Search clinical trials for: Ori-C101

Total 11813 results

OriCell Therapeutics Co., Ltd.

Recruiting

Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

Hepatocellular Carcinoma

China
Gilead Sciences

Terminated

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
ORIC Pharmaceuticals

Completed

Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects

Healthy Volunteers

United Kingdom
ORIC Pharmaceuticals

Completed

Study of ORIC-101 in Healthy Adult Subjects

Healthy Volunteers

United States
Ornovi, Inc.

Withdrawn

A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects

Alopecia Areata

Australia
ORIC Pharmaceuticals

Terminated

Study of ORIC-101 in Combination With Enzalutamide

Prostatic Neoplasms

United States
Michael C Roarke, MD

Completed

Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma

Multiple Myeloma

United States
Gilead Sciences

Withdrawn

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
MorphoSys AG

Completed

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, United Kingdom, Austria, Germany, Italy, Poland
Gilead Sciences

Completed

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Allergic Rhinitis

Austria
JW Pharmaceutical

Completed

To Evaluate the Safety and PK Characteristics in Healthy Volunteers

Healthy

Korea, Republic of
Gilead Sciences

Terminated

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States
NYU Langone Health

Recruiting

Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI

Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection

United States
Gilead Sciences

Completed

Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin Lymphoma | Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)

Japan
Gilead Sciences

Completed

Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Dana-Farber Cancer Institute
Gilead Sciences

Terminated

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia

United States
Gilead Sciences

Completed

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas (DELTA)

Follicular Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma

United States, United Kingdom, Italy, Germany, Poland, France
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma and other conditions

United States
Chordate Medical

Completed

Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic Rhinitis (KOSNAR)

Nasal Congestion | Non-allergic Rhinitis

Finland, Italy, United Kingdom, Greece, Netherlands, Czechia
Can-Fite BioPharma

Completed

Safety and Efficacy Study of CF101 to Treat Psoriasis

Plaque Psoriasis

Israel
Gilead Sciences

Terminated

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease (Madison)

Myelofibrosis

United States
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States, Spain, Belgium, Canada, United Kingdom, Australia, Denmark, Poland, Ireland, France, Sweden
Gilead Sciences

Terminated

Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

Chronic Lymphocytic Leukemia

United States, France, United Kingdom, Germany, Italy
University Hospital, Ghent

Withdrawn

Is Ultrasonography Comparable to MRI for the Detection of Morton Neuroma of the Foot?

Morton Neuroma
Memorial Sloan Kettering Cancer Center

Recruiting

Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment

Radiation Therapy

United States
Forma Therapeutics, Inc.
ProSciento, Inc.

Terminated

A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

Nonalcoholic Steatohepatitis (NASH) | Overweight or Obesity

United States
Medical University Innsbruck
Ruth Kröss, MD EDAIC; Glodny Bernhard, MD PD Assoc. Prof.; Laura Trefzer, Cand... and other collaborators

Completed

Soft Tissue and Bone Diameter in Children and Adults for Intraosseus Access

Emergencies | Bone Infection | Infusion Site Injury

Austria
GeneCradle Inc

Recruiting

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients

SMA II

China
Cognition Pharmaceuticals, LLC

Completed

A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis

Multiple Sclerosis | Cognition Disorders

United States
JW Pharmaceutical

Completed

To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension

Hypertension | Dyslipidemia

Korea, Republic of
Addpharma Inc.

Completed

Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102

Hypertension

Korea, Republic of
Gilead Sciences
Boehringer Ingelheim

Terminated

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL)

United States
GeneCradle Inc

Recruiting

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients

Spinal Muscular Atrophy Type 3

China
GeneCradle Inc

Recruiting

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

Spinal Muscular Atrophy

China
Gilead Sciences

Terminated

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Follicular Lymphoma

Spain, Italy, France, Poland, Israel, United Kingdom, Czechia, Romania, Australia, Canada
Fudan University

Unknown

Application of Radiomics in Precise Preoperative Diagnosis and Prognsis Evaluation of Colorectal Cancer.

Colorectal Cancer Stage I-IV

China
Scripps Health
Boston Scientific Corporation; Abbott Medical Devices; Biotronik, Inc.; Scripps...

Completed

The MagnaSafe Registry: Determining the Risks of Magnetic Resonance Imaging (MRI) in the Presence of Pacemakers and Implantable Cardioverter Defibrillators (ICDs) (MagnaSafe)

Need for MRI Imaging With Pacemaker or | Implantable Cardioverter Defibrillator Implanted

United States
Hoffmann-La Roche

Active, not recruiting

RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease

Crohn Disease

United States, Belgium, Hungary, France, Poland, Canada, Bulgaria, Spain, Germany, Slovakia
Endo Pharmaceuticals

Completed

Vantas Implant Retrieval Study

Prostate Cancer
Hoffmann-La Roche

Active, not recruiting

RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease

Crohn Disease

United States, France, Poland, Hungary, Spain
Response Pharmaceuticals

Completed

Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension

Hypertension

Germany
Response Pharmaceuticals

Completed

Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension

Hypertension

United Kingdom
Liu Zi

Enrolling by invitation

Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies

Genital Neoplasms, Female

China
Fudan University

Recruiting

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Refractory Malignant Ascites

China
Finch Research and Development LLC.

Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) (PRISM4)

Recurrent C. Difficile Infection

United States, Canada
MacuCLEAR, Inc.

Terminated

Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration

Nonexudative Age Related Macular Degeneration

United States
TR Therapeutics

Completed

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Wounds

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Active, not recruiting

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

Advanced Prostate Cancer

United States

Search clinical trials for: Ori-C101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations